drugset / Trial / NCT06178679

Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED)

NCT06178679 ↗

Phase 3 Unknown 175 enrolled ORA, Inc. Stuart Therapeutics, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

A Phase 3 Multi-Center, Randomized, Double Masked, Vehicle Controlled Study to Assess the Safety and Efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed with Dry Eye Disease (DED)

Timeline

Start
2023-12-29
Primary completion
2024-06-30
Completion
2024-07-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject vezocolmitide Protein / enzyme biologic 60 ug/ml Topical

Indications